Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer

Overview of attention for article published in Oncotarget, January 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#33 of 14,341)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 52 news stories from 43 outlets.

Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of…

Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of…

Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of…

Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 48 additional news stories.